One of the digital health sector's latest unicorn companies – Biofourmis – has upscaled its recent fourth round financing, adding $20 million to the $300 million it
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh